Post by TherapeutAix

Inhaled therapies are gaining momentum in IPF. At this year’s European Respiratory Society meeting, new data underscored how inhalation could overcome one of the biggest hurdles in idiopathic pulmonary fibrosis (IPF) treatment: the additive gastrointestinal side effects seen when combining oral therapies. From nebulised treprostinil meeting its Phase 3 endpoint, to inhaled nintedanib (AP02) entering clinical testing, and LTI-03 advancing to Phase 2, a new wave of approaches is reshaping what’s possible. In our latest blog, we explore how these developments could redefine combination therapy in IPF and highlight why delivery route matters more than ever. 👉 Read more at https://lnkd.in/e8r-DHtZ #IPF #pulmonaryfibrosis #drugdevelopment #inhaledtherapy #translationalresearch #TherapeutAix